Could fewer doses of targeted radiation control prostate cancer just as well?
NCT ID NCT06200103
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 35 times
Summary
This study is for people with a type of advanced prostate cancer that has spread and no longer responds to hormone therapy. It compares the standard 6 cycles of a targeted radiation drug (Lu-177 PSMA-617) against stopping after 5 cycles, to see if the shorter course can control the cancer just as well while reducing side effects and treatment burden. About 236 participants will be randomly assigned to one of the two treatment plans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.